基于肌酐与胱抑素C的估算肾小球滤过率不一致性与临床结局:一项Meta分析
该研究基于慢性肾脏病预后联盟(CKD-PC)个体水平Meta分析,纳入23个门诊队列821 327人及2个住院队列39 639人,评估胱抑素C估算肾小球滤过率(eGFRcys)较肌酐估算值(eGFRcr)低至少30%的大幅负向差异的患病率及其与不良结局的关联。门诊中11%存在该差异,住院患者为35%;门诊中该差异与全因死亡、心血管死亡、动脉粥样硬化性心血管病、心力衰竭及需替代治疗的肾衰竭风险升高相关。
要点
- 门诊人群11%存在eGFRcys较eGFRcr低至少30%的大幅负向差异,住院患者为35%。
- 门诊中该差异与全因死亡风险升高相关(HR 1.69,95%CI 1.57-1.82)。
- 门诊中该差异与心血管死亡、动脉粥样硬化性心血管病、心力衰竭及需替代治疗的肾衰竭风险升高相关。
核心结论
- 在CKD-PC中,11%的门诊参与者和35%的住院患者eGFRcys较eGFRcr低至少30%。
- 在门诊环境中,eGFRcys较eGFRcr低至少30%与全因死亡、心血管事件及肾衰竭发生率显著升高相关。
研究设计与样本
- 研究数据来自慢性肾脏病预后联盟(CKD-PC)的参与者。
- 纳入同时有胱抑素C和肌酐测量及临床结局测量的参与者。
- 于2024年4月至2025年8月间采用个体水平Meta分析合成数据。
- 共纳入23个门诊队列的821 327人(平均[SD]年龄59[12]岁;48%女性;13.5%患糖尿病;40%患高血压)及2个住院队列的39 639人(平均[SD]年龄67[16]岁;31%女性;30%患糖尿病;72%患高血压)。
主要发现
- 门诊参与者中11%存在大幅负向eGFRdiff(范围3%-50%),住院患者中为35%。
- 门诊参与者平均(SD)随访11(4)年,大幅负向eGFRdiff(eGFRcys较eGFRcr低至少30%)相较于eGFRdiff在-30%至30%之间,全因死亡率分别为28.4 vs 16.8/1000人年(HR 1.69,95%CI 1.57-1.82)。
- 心血管死亡率分别为6.1 vs 3.8/1000人年(HR 1.61,95%CI 1.48-1.76)。
- 动脉粥样硬化性心血管病发生率分别为13.3 vs 9.8/1000人年(HR 1.35,95%CI 1.27-1.44)。
- 心力衰竭发生率分别为13.2 vs 8.6/1000人年(HR 1.54,95%CI 1.40-1.68);需替代治疗的肾衰竭发生率分别为2.7 vs 2.1/1000人年(HR 1.29,95%CI 1.13-1.47)。
关键数值与推荐
- 主要独立测量指标为大幅负向eGFR差异(eGFRdiff),定义为eGFRcys较eGFRcr低至少30%。
- 次要(依赖)结局包括全因死亡、心血管死亡、动脉粥样硬化性心血管病、心力衰竭及需替代治疗的肾衰竭。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Estimated glomerular filtration rates (eGFRs) can differ according to whether creatinine or cystatin C is used for the eGFR calculation, but the prevalence and importance of these differences remain unclear. OBJECTIVES: To evaluate the prevalence of a discordance between cystatin C-based eGFR (eGFRcys) and creatinine-based eGFR (eGFRcr), identify characteristics associated with greater discordance, and evaluate associations of discordance with adverse outcomes. DATA SOURCES: Participants in the Chronic Kidney Disease Prognosis Consortium (CKD-PC). STUDY SELECTION: Participants with concurrent cystatin C and creatinine measurements and clinical outcome measurement. DATA EXTRACTION AND SYNTHESIS: Between April 2024 and August 2025, data were synthesized using individual-level meta-analysis. MAIN OUTCOMES AND MEASURES: The primary independent measurement was a large negative eGFR difference (eGFRdiff), defined as an eGFRcys that was at least 30% lower than eGFRcr. Secondary (dependent) outcomes included all-cause and cardiovascular mortality, atherosclerotic cardiovascular disease, heart failure, and kidney failure with replacement therapy. RESULTS: A total of 821 327 individuals from 23 outpatient cohorts (mean [SD] age, 59 [12] years; 48% female; 13.5% with diabetes; 40% with hypertension) and 39 639 individuals from 2 inpatient cohorts (mean [SD] age, 67 [16] years; 31% female; 30% with diabetes; 72% with hypertension) were included. Among outpatient participants, 11% had a large negative eGFRdiff (range, 3%-50%). Among inpatients, 35% had a large negative eGFRdiff. Among outpatient participants, at a mean (SD) follow-up of 11 (4) years, a large negative eGFRdiff, compared with an eGFRdiff between -30% and 30%, was associated with higher rates of all-cause mortality (28.4 vs 16.8 per 1000 person-years [PY]; hazard ratio [HR], 1.69 [95% CI, 1.57-1.82]), cardiovascular mortality (6.1 vs 3.8 per 1000 PY; HR, 1.61 [95% CI, 1.48-1.76]), atherosclerotic cardiovascular disease (13.3 vs 9.8 per 1000 PY; HR, 1.35 [95% CI, 1.27-1.44]), heart failure (13.2 vs 8.6 per 1000 PY; HR, 1.54 [95% CI, 1.40-1.68]), and kidney failure with replacement therapy (2.7 vs 2.1 per 1000 PY; HR, 1.29 [95% CI, 1.13-1.47]). CONCLUSIONS AND RELEVANCE: In the CKD-PC, 11% of outpatient participants and 35% of hospitalized patients had an eGFRcys that was at least 30% lower than their eGFRcr. In the outpatient setting, presence of eGFRcys at least 30% lower than eGFRcr was associated with significantly higher rates of all-cause mortality, cardiovascular events, and kidney failure.
引用
- Estrella MM, Ballew SH, Sang Y, et al. Discordance in Creatinine- and Cystatin C-Based eGFR and Clinical Outcomes: A Meta-Analysis. JAMA. 2025. PMID: 41202182. doi:10.1001/jama.2025.17578
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。